Results 51 to 60 of about 37,793 (186)

Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis

Swiss Medical Weekly, 2023
AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill, Plamenna Venkova-Marchevska, Huldrych F. Günthard, Sara Botero-Mesa, Amaury Thiabaud, Maroussia Roelens, Laure Vancauwenberghe, Lauro Damonti, Ulrich Heininger, Anne Iten, Peter W. Schreiber, Rami Sommerstein, Sarah Tschudin-Sutter, Nicolas Troillet, Danielle Vuichard-Gysin, Andreas Widmer, Torsten Hothorn, Olivia Keiser   +17 more
doaj   +1 more source

Remdesivir: A Review in COVID-19

, 2023
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of ...
Hannah A. Blair (6846307)
core   +1 more source

Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study

Journal of Microbiology, Immunology and Infection
Background: Remdesivir has been used to treat severe coronavirus 2019 (COVID-19); however, its safety and effectiveness in patients remain unclear. This study aimed to investigate the safety and effectiveness of remdesivir in patients with COVID-19 with ...
Yan-Bo Huang, Chip-Jin Ng, Cheng-Hsun Chiu, Chung-Hsien Chaou, Shi-Ying Gao, Shou-Yen Chen   +5 more
doaj   +1 more source

Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study

Scientific Reports, 2022
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan.
Kazuhito Miyazaki, Yukihiro Yoshimura, Nobuyuki Miyata, Hiroaki Sasaki, Aya Shiba, Masaharu Aga, Yusuke Hamakawa, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Tsuneo Shimokawa, Hiroaki Okamoto, Natsuo Tachikawa   +12 more
doaj   +1 more source

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis

Case Reports in Infectious Diseases, 2020
Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials.
Vincent Peyko, Helena Ladd, Anthony Cutrona   +2 more
doaj   +1 more source

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Case Reports in Women's Health, 2020
Summary: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus ...
Jonathon Anderson, Jordan Schauer, Suzanne Bryant, Cornelia R. Graves   +3 more
doaj   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports

Renal Replacement Therapy, 2022
Background The mortality rate of novel coronaviral disease (COVID-19) patients undergoing dialysis is considerably higher than that of patients with normal kidney function.
Jun Ito, Moritsugu Kimura, Tomoyuki Toya, Konomi Isozumi, Atsuro Kawaji, Yudai Isozaki, Masafumi Fukagawa   +6 more
doaj   +1 more source

Safety and heart rate changes in Covid-19 patients treated with Remdesivir

International Journal of Infectious Diseases, 2021
Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir.
Natale Daniele Brunetti, MD, PhD, Mariacristina Poliseno, MD, Irene Francesca Bottalico, MD, Antonio Centola, MD, Laura Montemurro, MD, Salvatore Sica, MD, Teresa Santantonio, MD, Sergio Lo Caputo, MD   +7 more
doaj   +1 more source

Membrane‐Permeable Nucleoside T‐1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides

Chemistry – A European Journal, EarlyView.
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier, Duan Li, Leentje Persoons, Graciela Andrei, Robert Snoeck, Dominique Schols, Lieve Naesens, Xiao Jia   +7 more
wiley   +1 more source